Five things for pharma marketers to know: Friday, September 25, 2020
NY to conduct its own COVID-19 vaccine review; U.K. experiences resurgence in coronavirus cases; Join us for MM+M Transform Sept. 30 and Oct. 1.
Roundup
Five things for pharma marketers to know: Thursday, September 24, 2020
U.S. health officials testify before Congress; J&J begins late-stage vaccine trial; AstraZeneca’s COVID-19 vaccine trial remains under investigation by FDA.
Five things for pharma marketers to know: Wednesday, September 23, 2020
FDA to issue guidance outlining tougher standards for a COVID-19 vaccine; Biden campaign balances criticizing Trump’s vaccine efforts with encouraging trust in vaccines; U.S. surpasses 200,000 deaths from coronavirus.
Five things for pharma marketers to know: Tuesday, September 22, 2020
CDC reverses stance on airborne transmission of COVID-19; Group of Black doctors to independently vet COVID-19 decisions; Join the virtual MM+M Hall of Femme today.
Five things for pharma marketers to know: Monday, September 21, 2020
CDC rescinds COVID-19 testing guidance; State treasurers ask Gilead to lower remdesivir price; Expert breaks down early pandemic messaging mishaps.
Five things for pharma marketers to know: Friday, September 18, 2020
Moderna expects to know if COVID-19 vaccine is safe by Nov.; NY files opioid lawsuit against J&J; #WhoSavesTheirLives: An initiative advocating better support for HCPs.
Five things for pharma marketers to know: Thursday, September 17, 2020
U.S. plans to distribute vaccine within 24 hours of approval; CDC needs $6B to distribute a potential vaccine nationwide; Eli Lilly’s antibody helped reduce hospitalization for coronavirus patients.
Five things for pharma marketers to know: Wednesday, September 16, 2020
Court upholds New York law requiring drugmakers to fund opioid programs; More Black and Hispanic children are dying from coronavirus; Eli Lilly’s rheumatoid arthritis drug helps speed recovery in COVID-19 patients.
Five things for pharma marketers to know: Tuesday, September 15, 2020
Study suggests genes play a role in COVID-19; U.S. AstraZeneca vaccine trial remains on hold; Gilead acquired cancer drugmaker Immunomedics for $21B.
Five things for pharma marketers to know: Monday, September 14, 2020
NIH begins studies of blood thinners to treat COVID-19; Global vaccine trust may be a challenge for COVID-19 vaccination; Register to attend MM+M’s upcoming webcast on maximizing marketing efforts.
Five things for pharma marketers to know: Friday, September 11, 2020
Teen vaping dropped significantly last year; Public trust in CDC, health officials is falling; Democrats accuse CMS head Seema Verma of abusing taxpayer dollars.
Five things for pharma marketers to know: Thursday, September 10, 2020
AstraZeneca pauses COVID-19 vaccine trial; Coronavirus deaths in U.S. surpass 190,000; Mail-order prescriptions experience delays.
Five things for pharma marketers to know: Wednesday, September 9, 2020
Pharma companies pledge to only seek approval for safe and effective COVID-19 vaccines; A vaccine before the November election is unlikely, Fauci says; Uber Health head to depart.
Five things for pharma marketers to know: Tuesday, September 8, 2020
Join us for the MM&M Hall of Femme event; Register to attend our virtual conference MM&M Transform; Save the date for the 40 Under 40 event.
Five things for pharma marketers to know: Friday, September 4, 2020
Pfizer hopes for late-stage COVID vaccine results in Oct.; Amarin loses Vascepa patent appeal; Submit questionnaires for 2020 MM+M Best Places to Work.
Want to read more?
Please login or register first to view this content.
